Squarepoint’s Ascendis Pharma A/S ASND Stock Holding History

Squarepoint’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Buy	+9,686	New	+$2.26M	﹤0.01%	2135
2026 Q1	–	Sell	-6,474	Closed	-$1.45M	–	4247
2025 Q4	$1.38M	Buy	6,474 +5,271	+438%	+$1.09M	﹤0.01%	2344
2025 Q3	$239K	Sell	1,203 -3,994	-77%	-$745K	﹤0.01%	3823
2025 Q2	$897K	Buy	+5,197	New	+$847K	﹤0.01%	2762
2024 Q1	–	Sell	-5,881	Closed	-$741K	–	3998
2023 Q4	$741K	Buy	+5,881	New	+$586K	﹤0.01%	2734
2023 Q3	–	Sell	-11,125	Closed	-$993K	–	3762
2023 Q2	$993K	Buy	+11,125	New	+$968K	﹤0.01%	2168
2022 Q4	–	Sell	-17,329	Closed	-$1.79M	–	3167
2022 Q3	$1.79M	Buy	17,329 +13,609	+366%	+$1.29M	0.01%	1393
2022 Q2	$346K	Buy	+3,720	New	+$351K	﹤0.01%	2213
2022 Q1	–	Sell	-1,826	Closed	-$246K	–	2794
2021 Q4	$246K	Sell	1,826 -2,082	-53%	-$310K	﹤0.01%	2567
2021 Q3	$623K	Sell	3,908 -2,569	-40%	-$352K	﹤0.01%	1828
2021 Q2	$852K	Buy	+6,477	New	+$863K	﹤0.01%	1754
2020 Q4	–	Sell	-3,166	Closed	-$489K	–	2897
2020 Q3	$489K	Buy	+3,166	New	+$455K	0.01%	1452
2020 Q2	–	Sell	-3,420	Closed	-$385K	–	2215
2020 Q1	$385K	Buy	+3,420	New	+$444K	0.01%	1175
2019 Q2	–	Sell	-7,379	Closed	-$869K	–	2357
2019 Q1	$869K	Buy	7,379 +4,119	+126%	+$361K	0.01%	1175
2018 Q4	$204K	Buy	+3,260	New	+$205K	﹤0.01%	1676
2018 Q3	–	Sell	-4,300	Closed	-$286K	–	1973
2018 Q2	$286K	Sell	4,300 -1,200	-22%	-$78.9K	﹤0.01%	1398
2018 Q1	$360K	Buy	+5,500	New	+$309K	0.01%	1227

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Squarepoint's ASND Position: Q2 2026 in Review

Squarepoint opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 9,686 shares worth $2.58M. The stake represents ﹤0.01% of the portfolio and ranks #2135 among its holdings. This is a return to the name: Squarepoint previously reported a position in ASND as recently as Q4 2025.

Squarepoint first reported a position in ASND in Q1 2018 and has held it in 17 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Squarepoint held 9,686 shares of Ascendis Pharma A/S worth $2.58M as of Q2 2026.
Ascendis Pharma A/S was a new Squarepoint position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2135 holding.
Squarepoint first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 17 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.